Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))

Toni K. Choueiri; Colin Hessel; Susan Halabi; Ben Sanford; M. Dror Michaelson; Olwen Hahn; Meghara Walsh; Thomas Olencki; Joel Picus; Eric J. Small; Shaker Dakhil; Darren R. Feldman; Milan Mangeshkar; Christian Scheffold; Daniel George; Michael J. Morris

doi:10.1016/j.ejca.2018.09.022

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))

Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel George, Michael J. Morris

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.

Original language	English
Number of pages	1
Journal	European Journal of Cancer
Volume	103
DOIs	https://doi.org/10.1016/j.ejca.2018.09.022
State	Published - Nov 2018

Access to Document

10.1016/j.ejca.2018.09.022

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))'. Together they form a unique fingerprint.

Cite this

Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., Dakhil, S., Feldman, D. R., Mangeshkar, M., Scheffold, C., George, D., & Morris, M. J. (2018). Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012)). European Journal of Cancer, 103. https://doi.org/10.1016/j.ejca.2018.09.022

Choueiri, Toni K. ; Hessel, Colin ; Halabi, Susan ; Sanford, Ben ; Michaelson, M. Dror ; Hahn, Olwen ; Walsh, Meghara ; Olencki, Thomas ; Picus, Joel ; Small, Eric J. ; Dakhil, Shaker ; Feldman, Darren R. ; Mangeshkar, Milan ; Scheffold, Christian ; George, Daniel ; Morris, Michael J. / Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) : Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012)). In: European Journal of Cancer. 2018 ; Vol. 103.

@article{a6e5cf2b0b454137b4c90594b940c3a8,

title = "Corrigendum to {\textquoteleft}Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update{\textquoteright} [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))",

abstract = "The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.",

author = "Choueiri, {Toni K.} and Colin Hessel and Susan Halabi and Ben Sanford and Michaelson, {M. Dror} and Olwen Hahn and Meghara Walsh and Thomas Olencki and Joel Picus and Small, {Eric J.} and Shaker Dakhil and Feldman, {Darren R.} and Milan Mangeshkar and Christian Scheffold and Daniel George and Morris, {Michael J.}",

year = "2018",

month = nov,

doi = "10.1016/j.ejca.2018.09.022",

language = "English",

volume = "103",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Choueiri, TK, Hessel, C, Halabi, S, Sanford, B, Michaelson, MD, Hahn, O, Walsh, M, Olencki, T, Picus, J, Small, EJ, Dakhil, S, Feldman, DR, Mangeshkar, M, Scheffold, C, George, D & Morris, MJ 2018, 'Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))', European Journal of Cancer, vol. 103. https://doi.org/10.1016/j.ejca.2018.09.022

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) : Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012)). / Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.

In: European Journal of Cancer, Vol. 103, 11.2018.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial)

T2 - Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))

AU - Choueiri, Toni K.

AU - Hessel, Colin

AU - Halabi, Susan

AU - Sanford, Ben

AU - Michaelson, M. Dror

AU - Hahn, Olwen

AU - Walsh, Meghara

AU - Olencki, Thomas

AU - Picus, Joel

AU - Small, Eric J.

AU - Dakhil, Shaker

AU - Feldman, Darren R.

AU - Mangeshkar, Milan

AU - Scheffold, Christian

AU - George, Daniel

AU - Morris, Michael J.

PY - 2018/11

Y1 - 2018/11

N2 - The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.

AB - The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85054008620&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.09.022

DO - 10.1016/j.ejca.2018.09.022

M3 - Comment/debate

C2 - 30270112

AN - SCOPUS:85054008620

VL - 103

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O et al. Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012)). European Journal of Cancer. 2018 Nov;103. https://doi.org/10.1016/j.ejca.2018.09.022